Publicaciones (55) Publicaciones de ESTHER CONDE GALLEGO

2024

  1. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach

    Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326

  2. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

  3. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

2023

  1. A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma

    Translational Lung Cancer Research, Vol. 12, Núm. 7, pp. 1549-1562

  2. Caracterización y clasificación molecular del cáncer de pulmón

    Revisiones en Cancer, Vol. 37, Núm. 3, pp. 114-120

  3. Correction to: New update to the guidelines on testing predictive biomarkers in non‑small‑cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2022), 10.1007/s12094-022-03046-9)

    Clinical and Translational Oncology

  4. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 56, Núm. 2, pp. 97-112

  5. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 25, Núm. 5, pp. 1252-1267

  6. Pan-TRK Immunohistochemistry to Optimize the Detection of NTRK Fusions: Removing the Hay When Looking for the Needle

    Modern Pathology

  7. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe

    ESMO Open, Vol. 8, Núm. 5

2022

  1. Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain

    BMC Cancer, Vol. 22, Núm. 1

  2. Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy

    Journal of Clinical Medicine, Vol. 11, Núm. 6

  3. Molecular diagnosis in non-small-cell lung cancer: Expert opinion on ALK and ROS1 testing

    Journal of Clinical Pathology, Vol. 75, Núm. 3, pp. 145-153

  4. Rethinking the role of biomarkers for operable non-small cell lung carcinoma: an effective collaboration with artificial intelligence algorithms

    Modern Pathology

2021

  1. Erratum: Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients with NTRK Fusion Cancer (Arch Pathol Lab Med (2021) 145: 4 (441–447) DOI: 10.5858/arpa.2020-0042-OA)

    Archives of Pathology and Laboratory Medicine

  2. Lung Cancer in Spain

    Journal of Thoracic Oncology

  3. Pan-TRK immunohistochemistry an example-based practical approach to efficiently identify patients with NTRK fusion cancer

    Archives of Pathology and Laboratory Medicine, Vol. 145, Núm. 8, pp. 1031-1040

  4. Screening for ROS1 fusions in patients with advanced non-small cell lung carcinomas using the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody

    Expert Review of Molecular Diagnostics, Vol. 21, Núm. 5, pp. 437-444

  5. Targeted therapy moves to earlier stages of non-small-cell lung cancer: Emerging evidence, controversies and future challenges

    Future Oncology, Vol. 17, Núm. 30, pp. 4011-4025

2020

  1. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens

    Cancer Cytopathology, Vol. 128, Núm. 12, pp. 928-938